Evaluation of effects on immune function is an essential component of safety evaluation of new drugs and biotechnology products. Changes in immunity may signify toxic side effects of therapeutic drugs; thus, immunologic assessments are critical for evaluating drug or chemical impact on human health. Enhanced immune evaluations are often needed for small-molecule synthetic drugs, peptides and nucleic-acid-based biotherapeutics, such as antisense agents, as well as biotechnology products (e.g., recombinant human proteins), especially those for broad or chronic human use or for use in sensitive populations. When built into toxicology studies, immune end points are valuable for understanding of expected human target doses.
TICRO’s animal models facilitate the evaluation of candidate therapeutics, vaccines and adjuvants for toxic side effects leading to impaired immune cell function and impaired immunity to infections. We offer murine models of infection using a broad range of pathogens, with a focus on respiratory infections, including: Influenza A and B viruses, Mycobacterium tuberculosis, Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Yersinia enterocolitica, Yersinia pestis, Listeria monocytogenes, Campylobacter jejunii, and Francisella tularensis (strain LVS).
For more information, please contact:
William Reiley, Ph.D.
Senior CRO Program Manager
(518) 891-3080, ext. 315